

Jianfeng Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033489/publications.pdf>

Version: 2024-02-01

243
papers

6,936
citations

117625

34
h-index

91884

69
g-index

259
all docs

259
docs citations

259
times ranked

13541
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisnelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1147-1156.	7.0	23
2	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. <i>Modern Pathology</i> , 2022, 35, 632-639.	5.5	6
3	A Reversible Chemogenetic Switch for Chimeric Antigen Receptor Tâ€¦Cells**. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	13.8	8
4	Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study. <i>Annals of Translational Medicine</i> , 2022, 10, 30-30.	1.7	4
5	Infection complications in febrile chimeric antigen receptor (CAR)â€¦ recipients during the periâ€¦CARâ€¦ cell treatment period examined using metagenomic nextâ€¦generation sequencing (mNGS). <i>Cancer Communications</i> , 2022, 42, 476-480.	9.2	15
6	The development and progress of nanomedicine for esophageal cancer diagnosis and treatment. <i>Seminars in Cancer Biology</i> , 2022, 86, 873-885.	9.6	44
7	Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
8	A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy. <i>Frontiers in Pharmacology</i> , 2022, 13, 803693.	3.5	6
9	Osteopontin is required for the maintenance of leukemia stem cells in acute myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2022, 600, 29-34.	2.1	2
10	Titelbild: A Reversible Chemogenetic Switch for Chimeric Antigen Receptor Tâ€¦Cells (Angew. Chem.) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.9	0
11	Efficacy and safety of CD19-specific CAR T cellâ€¦based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. <i>Blood</i> , 2022, 139, 3376-3386.	1.4	36
12	CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2022, 24, 841-849.	0.7	12
13	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. <i>Blood</i> , 2022, 139, 3148-3158.	1.4	43
14	T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 85.	17.1	26
15	Acidâ€¦Responsive Aggregated Gold Nanoparticles for Radiosensitization and Synergistic Chemoradiotherapy in the Treatment of Esophageal Cancer. <i>Small</i> , 2022, 18, e2200115.	10.0	28
16	Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1589-1597.	1.3	1
17	A twoâ€¦part, singleâ€¦arm, multicentre, phase I study of zanubrutinib, a selective <sc>Bruton tyrosine kinase</sc> inhibitor, in Chinese patients with relapsed/refractory Bâ€¦cell malignancies. <i>British Journal of Haematology</i> , 2022, 198, 62-72.	2.5	10
18	CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 361-366.	2.0	0

#	ARTICLE	IF	CITATIONS
19	Autophagy inhibitors enhance biomolecular delivery efficiency of extracellular vesicles. <i>Biochemical and Biophysical Research Communications</i> , 2022, 603, 130-137.	2.1	3
20	The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK cell lymphoproliferative diseases. <i>Hematological Oncology</i> , 2022, 40, 381-389.	1.7	6
21	Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 101.	17.1	15
22	Prognostic Value of Geriatric Nutritional Risk Index in Esophageal Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Nutrition</i> , 2022, 9, 831283.	3.7	11
23	T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 873789.	4.8	4
24	Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 817969.	2.8	2
25	Emerging role of nanoparticles in the diagnostic imaging of gastrointestinal cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 580-594.	9.6	11
26	In patients undergoing esophagectomy does postoperative home enteral nutrition have any impact on nutritional status?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, , .	1.1	0
27	Overcoming resistance to anti-CD19 CAR T cell therapy in B cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 821-834.	1.7	3
28	Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	8
29	Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30 ⁺ lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7532-7532.	1.6	1
30	Abstract 2811: CT120, a novel fully human anti-CD19 x anti-CD22 dual targeted chimeric antigen receptor T cell product for the treatment of B-NHL and B-ALL. <i>Cancer Research</i> , 2022, 82, 2811-2811.	0.9	0
31	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. <i>Cancers</i> , 2022, 14, 3230.	3.7	23
32	Phase I study of the efficacy and safety of IBI319 in patients with advanced malignant tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2646-2646.	1.6	1
33	Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1154-1167.	2.9	5
34	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162.	4.4	10
35	Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e198-e205.	0.4	10
36	CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2379-2384.	4.2	17

#	ARTICLE	IF	CITATIONS
37	Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T cell therapy. <i>Journal of Cellular Physiology</i> , 2021, 236, 5832-5847.	4.1	2
38	PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100437.	1.7	0
39	A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 137, 2890-2901.	1.4	100
40	Loss of MBD2 affects early T cell development by inhibiting the WNT signaling pathway. <i>Experimental Cell Research</i> , 2021, 398, 112400.	2.6	3
41	Dynamics of Blood Viral Load Is Strongly Associated with Clinical Outcomes in Coronavirus Disease 2019 (COVID-19) Patients. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 10-18.	2.8	34
42	HIF-1 α promotes the migration and invasion of cancer-associated fibroblasts by miR-210. , 2021, 12, 1794.		19
43	The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. <i>Frontiers in Oncology</i> , 2021, 11, 625872.	2.8	25
44	Single-cell transcriptomes of peripheral blood cells indicate and elucidate severity of COVID-19. <i>Science China Life Sciences</i> , 2021, 64, 1634-1644.	4.9	12
45	Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 664816.	3.7	17
46	A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. <i>Clinical and Translational Medicine</i> , 2021, 11, e346.	4.0	35
47	Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 646499.	2.8	3
48	A novel full-human CD22-CAR T cell therapy with potent activity against CD22 ^{low} B-ALL. <i>Blood Cancer Journal</i> , 2021, 11, 71.	6.2	17
49	COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. <i>Cell</i> , 2021, 184, 1895-1913.e19.	28.9	512
50	Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms. <i>European Journal of Human Genetics</i> , 2021, 29, 1312-1315.	2.8	21
51	Clinical and genetic features of Epstein-Barr virus-triggered late-onset primary hemophagocytic lymphohistiocytosis: Ten pedigrees study. <i>Clinical and Translational Medicine</i> , 2021, 11, e393.	4.0	1
52	TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy. <i>Diagnostics</i> , 2021, 11, 844.	2.6	2
53	Tisnelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19507-e19507.	1.6	1
54	Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3501.	12.8	40

#	ARTICLE	IF	CITATIONS
55	Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2021, 11, 3142-3157.	9.4	6
56	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. , 2021, 9, e002029.		4
57	Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder. <i>Frontiers in Oncology</i> , 2021, 11, 709370.	2.8	11
58	Association of emergence of new mutations in circulating tumor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 845.	2.6	0
59	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 131.	6.2	28
60	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2021, 27, 5492-5501.	7.0	19
61	CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 910.e1-910.e11.	1.2	26
62	The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. <i>Molecular Therapy</i> , 2021, 29, 2707-2722.	8.2	25
63	Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5290-5299.	5.2	40
64	Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. <i>Blood Cancer Journal</i> , 2021, 11, 168.	6.2	24
65	Advances in Universal CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 744823.	4.8	78
66	Upregulation of CD22 by Chidamide promotes CAR T cells functionality. <i>Scientific Reports</i> , 2021, 11, 20637.	3.3	10
67	Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications. <i>Frontiers in Oncology</i> , 2021, 11, 717242.	2.8	14
68	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 167.	17.0	21
69	Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 755866.	4.8	18
70	A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. <i>Leukemia</i> , 2021, , .	7.2	6
71	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	2.8	12
72	Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 748465.	2.8	12

#	ARTICLE	IF	CITATIONS
73	Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT). <i>Blood</i> , 2021, 138, 94-94.	1.4	1
74	Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C. <i>Oncogenesis</i> , 2021, 10, 79.	4.9	4
75	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. <i>Frontiers of Medicine</i> , 2021, 15, 783-804.	3.4	3
76	The association of complex genetic background with the prognosis of acute leukemia with ambiguous lineage. <i>Scientific Reports</i> , 2021, 11, 24290.	3.3	3
77	PAX5 haploinsufficiency induces low T cell infiltration in the cancer microenvironment via reduced chemokines. <i>Current Molecular Medicine</i> , 2021, 21, .	1.3	0
78	Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 824-826.	2.4	17
79	Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. <i>Leukemia</i> , 2020, 34, 533-542.	7.2	104
80	Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e176.	4.0	14
81	<p>Asymptomatic Subclinical Cases of Coronavirus Disease 2019 without Viral Transmission in Three Independent Families</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3267-3271.	2.7	2
82	Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 500.	2.9	34
83	Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. <i>Journal of Controlled Release</i> , 2020, 326, 455-467.	9.9	54
84	Clinical characteristics of hematological patients concomitant with COVID-19. <i>Cancer Science</i> , 2020, 111, 3379-3385.	3.9	14
85	SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. , 2020, 8, e000862.		33
86	CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain. <i>Frontiers in Oncology</i> , 2020, 10, 1306.	2.8	32
87	Scoring cytokine storm by the levels of MCP-3 and IL-8 accurately distinguished COVID-19 patients with high mortality. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 292.	17.1	32
88	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1453-1454.	2.9	1
89	Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia. <i>Cancer Medicine</i> , 2020, 9, 4941-4948.	2.8	10
90	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 48.	17.0	83

#	ARTICLE	IF	CITATIONS
91	CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. , 2020, 8, e000364.		14
92	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology, 2020, 146, 137-146.e3.	2.9	374
93	Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research, 2020, 26, 4216-4224.	7.0	126
94	Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. Targeted Oncology, 2020, 15, 365-375.	3.6	14
95	Identification of ALPPL2 as a Naive Pluripotent State-Specific Surface Protein Essential for Human Naive Pluripotency Regulation. Cell Reports, 2020, 30, 3917-3931.e5.	6.4	28
96	The utility of noninvasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma. British Journal of Haematology, 2020, 189, e45-e48.	2.5	20
97	Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2020, 5, 21.	17.1	13
98	Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood, 2020, 135, 17-27.	1.4	191
99	Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. Therapeutics and Clinical Risk Management, 2020, Volume 16, 567-578.	2.0	4
100	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. Current Research in Translational Medicine, 2020, 68, 111-118.	1.8	30
101	Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 992-994.	10.5	202
102	Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy, 2020, 22, 166-171.	0.7	27
103	Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis. British Journal of Haematology, 2020, 189, 72-83.	2.5	12
104	Clinical significance of increased PML-RARa transcripts after induction therapy for acute promyelocytic leukaemia. Annals of Medicine, 2020, 52, 233-238.	3.8	1
105	Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine, 2020, 54, 102731.	6.1	19
106	Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR. Journal of Molecular Diagnostics, 2020, 22, 699-707.	2.8	27
107	CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas. Blood, 2020, 136, 11-11.	1.4	2
108	Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood, 2020, 136, 516-519.	1.4	25

#	ARTICLE	IF	CITATIONS
109	Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.. Journal of Clinical Oncology, 2020, 38, 8034-8034.	1.6	6
110	Innovative strategies to advance CAR T cell therapy for solid tumors. American Journal of Cancer Research, 2020, 10, 1979-1992.	1.4	2
111	Fueling chimeric antigen receptor T cells with cytokines. American Journal of Cancer Research, 2020, 10, 4038-4055.	1.4	5
112	Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma. Blood, 2020, 136, 43-43.	1.4	0
113	Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial. Blood, 2020, 136, 42-43.	1.4	3
114	Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies. Blood, 2020, 136, 36-37.	1.4	0
115	Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood, 2020, 136, 17-17.	1.4	1
116	Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial. Blood, 2020, 136, 4-4.	1.4	0
117	Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas. Blood, 2020, 136, 38-38.	1.4	1
118	Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. , 2019, 7, 271.		45
119	Precise temporal regulation of Dux is important for embryo development. Cell Research, 2019, 29, 956-959.	12.0	85
120	Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer. Journal of Experimental Medicine, 2019, 216, 688-703.	8.5	145
121	Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation. EBioMedicine, 2019, 40, 92-105.	6.1	11
122	Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway. Cancer Medicine, 2019, 8, 3905-3917.	2.8	7
123	Determination of Epstein-Barr Virus-Infected Lymphocyte Cell Types in Peripheral Blood Mononuclear Cells as a Valuable Diagnostic Tool in Hematological Diseases. Open Forum Infectious Diseases, 2019, 6, ofz171.	0.9	14
124	2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. Biochemical and Biophysical Research Communications, 2019, 513, 1063-1069.	2.1	25
125	microRNA-222 promotes colorectal cancer cell migration and invasion by targeting MST3. FEBS Open Bio, 2019, 9, 901-913.	2.3	20
126	SLC39A6/ZIP6 is essential for zinc homeostasis and T-cell development in zebrafish. Biochemical and Biophysical Research Communications, 2019, 511, 896-902.	2.1	4

#	ARTICLE	IF	CITATIONS
127	A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. , 2019, 7, 51.		12
128	The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis. EBioMedicine, 2019, 49, 26-39.	6.1	3
129	Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. , 2019, 7, 315.		47
130	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Frontiers in Oncology, 2019, 9, 1237.	2.8	106
131	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematology,the, 2019, 6, e12-e19.	4.6	176
132	Rheb1 loss leads to increased hematopoietic stem cell proliferation and myeloid-biased differentiation <i>in vivo</i>. Haematologica, 2019, 104, 245-255.	3.5	15
133	Sintilimab for relapsed/refractory classical Hodgkinâ€™s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.. Journal of Clinical Oncology, 2019, 37, 7533-7533.	1.6	1
134	Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2019, 37, 8013-8013.	1.6	16
135	Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma. Human Gene Therapy, 2018, 29, 251-258.	2.7	11
136	Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling. Blood Cancer Journal, 2018, 8, 24.	6.2	5
137	PAX5 haploinsufficiency induce cancer cell dormancy in Raji cells. Experimental Cell Research, 2018, 367, 30-36.	2.6	4
138	MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL. Cancer Research, 2018, 78, 1632-1642.	0.9	15
139	FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 32.	8.6	19
140	Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells. Cancer Biology and Therapy, 2018, 19, 676-686.	3.4	13
141	Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Research, 2018, 28, 172-186.	12.0	62
142	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood, 2018, 131, 68-83.	1.4	311
143	M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. Blood Advances, 2018, 2, 859-870.	5.2	45
144	Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. Journal of Hematology and Oncology, 2018, 11, 128.	17.0	41

#	ARTICLE	IF	CITATIONS
145	miR-197 promotes the invasion and migration of colorectal cancer by targeting insulin-like growth factor-binding protein-1/23. <i>Oncology Reports</i> , 2018, 40, 2710-2721.	2.6	11
146	Selective bio-labeling and induced apoptosis of hematopoietic cancer cells using dual-functional polyethylenimine-caged platinum nanoclusters. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1465-1470.	2.1	14
147	Influence of various medium environment to in vitro human T cell culture. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 559-566.	1.5	24
148	Human MLL-AF9 Overexpression Induces Aberrant Hematopoietic Expansion in Zebrafish. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	5
149	Effects of cryopreservation on chimeric antigen receptor T cell functions. <i>Cryobiology</i> , 2018, 83, 40-47.	0.7	33
150	Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. <i>Blood Cancer Journal</i> , 2018, 8, 61.	6.2	10
151	CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies. <i>Blood</i> , 2018, 132, 1408-1408.	1.4	19
152	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL. <i>Blood</i> , 2018, 132, 2054-2054.	1.4	2
153	T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies. <i>Blood</i> , 2018, 132, 1013-1013.	1.4	33
154	Tislezumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study. <i>Blood</i> , 2018, 132, 682-682.	1.4	11
155	Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial. <i>Blood</i> , 2018, 132, 148-148.	1.4	37
156	Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7536-7536.	1.6	3
157	Droplet Digital PCR Monitoring of TP53 Mutated Circulating Tumor DNA Levels in Lymphoma Patients. <i>Blood</i> , 2018, 132, 4106-4106.	1.4	1
158	SHP-1 As a Negative Regulator of FLT3 Associated Aberrant Signaling and a New Potential Target to FLT3-ITD Mutation. <i>Blood</i> , 2018, 132, 4051-4051.	1.4	0
159	Clonal cytogenetic abnormalities are predictor in developing non-Hodgkin lymphomas?. <i>Experimental and Molecular Pathology</i> , 2017, 102, 146-155.	2.1	1
160	<i>PBX3</i> is essential for leukemia stem cell maintenance in <i>MLL</i> -rearranged leukemia. <i>International Journal of Cancer</i> , 2017, 141, 324-335.	5.1	34
161	Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines. <i>Oncology Letters</i> , 2017, 13, 4619-4626.	1.8	8
162	Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming. <i>Cell Death and Disease</i> , 2017, 8, e2870-e2870.	6.3	48

#	ARTICLE	IF	CITATIONS
163	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	17.0	155
164	HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. <i>Haematologica</i> , 2017, 102, 1956-1968.	3.5	9
165	The novel autophagy inhibitor elaiophyllin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis. <i>Cancer Biology and Therapy</i> , 2017, 18, 584-595.	3.4	30
166	Tumor necrosis factor $\hat{\pm}$ in the onset and progression of leukemia. <i>Experimental Hematology</i> , 2017, 45, 17-26.	0.4	47
167	AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes. <i>Experimental Hematology</i> , 2017, 45, 36-44.e2.	0.4	6
168	Identification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line. <i>BioMed Research International</i> , 2017, 2017, 1-9.	1.9	5
169	MicroRNA-222 influences migration and invasion through MIA3 in colorectal cancer. <i>Cancer Cell International</i> , 2017, 17, 78.	4.1	24
170	Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance. <i>Oncotarget</i> , 2017, 8, 82268-82279.	1.8	9
171	Saline is a more appropriate solution for microvesicles for flow cytometric analyses. <i>Oncotarget</i> , 2017, 8, 34576-34585.	1.8	2
172	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 846-846.	1.4	14
173	CYC1 Predicts Poor Prognosis in Patients with Breast Cancer. <i>Disease Markers</i> , 2016, 2016, 1-9.	1.3	16
174	Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. <i>PLoS ONE</i> , 2016, 11, e0147545.	2.5	10
175	Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy. <i>American Journal of the Medical Sciences</i> , 2016, 351, 473-479.	1.1	8
176	The Value of Thromboelastography for Bleeding Risk Prediction in Hematologic Diseases. <i>American Journal of the Medical Sciences</i> , 2016, 352, 502-506.	1.1	12
177	ZNRF1 can inhibit proliferation and stemness properties of leukemia NB4 cells. <i>Animal Cells and Systems</i> , 2016, 20, 179-185.	2.2	0
178	The Prognostic Value of D-Dimer in De Novo Acute Myeloid Leukemia. <i>American Journal of the Medical Sciences</i> , 2016, 352, 129-133.	1.1	5
179	Loss of <i>Mbd2</i> Protects Mice Against High-Fat Diet-Induced Obesity and Insulin Resistance by Regulating the Homeostasis of Energy Storage and Expenditure. <i>Diabetes</i> , 2016, 65, 3384-3395.	0.6	34
180	Circulating CD ¹⁴ ⁺ HLA ^{DR} ^{low} myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease. <i>Cancer Medicine</i> , 2016, 5, 1654-1669.	2.8	30

#	ARTICLE	IF	CITATIONS
181	The role of thromboelastography in predicting bleeding risk and guiding the administration of platelet transfusions in hematological patients: a cohort study. <i>Annals of Hematology</i> , 2016, 95, 1163-1168.	1.8	5
182	Search for the potential "second-hit" mechanism underlying the onset of familial hemophagocytic lymphohistiocytosis type 2 by whole-exome sequencing analysis. <i>Translational Research</i> , 2016, 170, 26-39.	5.0	10
183	Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0158827.	2.5	9
184	Mutations or copy number losses of <i>CD58</i> and <i>TP53</i> genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. <i>Oncotarget</i> , 2016, 7, 83294-83307.	1.8	38
185	Transmembrane TNF- β preferentially expressed by leukemia stem cells and blasts is a potent target for antibody therapy. <i>Blood</i> , 2015, 126, 1433-1442.	1.4	33
186	TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality. <i>Scientific Reports</i> , 2015, 5, 18454.	3.3	9
187	Synergistic defects of UNC13D and AP3B1 leading to adult hemophagocytic lymphohistiocytosis. <i>International Journal of Hematology</i> , 2015, 102, 488-492.	1.6	15
188	Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. <i>Nature Genetics</i> , 2015, 47, 158-163.	21.4	393
189	A novel "priming-boosting" strategy for immune interventions in cervical cancer. <i>Molecular Immunology</i> , 2015, 64, 295-305.	2.2	11
190	Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells. <i>Autophagy</i> , 2015, 11, 1849-1863.	9.1	99
191	Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 333-339.	2.1	19
192	Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3999-4006.	1.6	56
193	Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. <i>Oncotarget</i> , 2015, 6, 3784-3796.	1.8	19
194	Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model. <i>Current Pharmaceutical Design</i> , 2015, 21, 1645-1653.	1.9	2
195	The overwhelmingly positive response to Dasatinib of a patient with multiple blast crisis of chronic myeloid leukemia. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1460-6.	1.3	2
196	lkaros6 is associated with BCR-ABL1 and myeloid-associated antigens but indicates poor prognosis independently in Chinese adult B-cell acute lymphoblastic leukemia. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 8497-505.	1.3	0
197	Analysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 9676-83.	1.3	1
198	Non-secreting multiple myeloma switches to IgD of lamda type: a case report and review of literature. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 16984-90.	1.3	3

#	ARTICLE	IF	CITATIONS
199	Chronic myeloid leukemia with variation of translocation at (Ph) [ins (22;9) (q11;q21q34)]: a case report. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13707-10.	0.5	6
200	A Systematic Comparison of the Anti-Tumoural Activity and Toxicity of the Three Adv-TKs. <i>PLoS ONE</i> , 2014, 9, e94050.	2.5	10
201	Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model. <i>Cancer Biology and Therapy</i> , 2014, 15, 1153-1162.	3.4	3
202	Identification of functional cooperative mutations of SETD2 in human acute leukemia. <i>Nature Genetics</i> , 2014, 46, 287-293.	21.4	213
203	Rictor/mammalian target of rapamycin 2 regulates the development of notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3. <i>Experimental Hematology</i> , 2014, 42, 1031-1040.e4.	0.4	14
204	Zinc Finger Nucleases Targeting the Human Papillomavirus <i>E7</i> Oncogene Induce <i>E7</i> Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells. <i>Clinical Cancer Research</i> , 2014, 20, 6495-6503.	7.0	49
205	MBD2 regulates TH17 differentiation and experimental autoimmune encephalomyelitis by controlling the homeostasis of T-bet/Hlx axis. <i>Journal of Autoimmunity</i> , 2014, 53, 95-104.	6.5	39
206	Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. <i>Translational Research</i> , 2014, 163, 565-577.	5.0	28
207	Trichostatin A Targets the Mitochondrial Respiratory Chain, Increasing Mitochondrial Reactive Oxygen Species Production to Trigger Apoptosis in Human Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e91610.	2.5	36
208	Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. <i>Oncotarget</i> , 2014, 5, 8416-8428.	1.8	50
209	NOTCH1 Transcriptionally Activates Deptor and Promotes AKT Activation in Acute T-Cell Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 895-895.	1.4	0
210	Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4239-46.	0.5	5
211	Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 4357-68.	1.3	17
212	Ubiquitin B in Cervical Cancer: Critical for the Maintenance of Cancer Stem-Like Cell Characters. <i>PLoS ONE</i> , 2013, 8, e84457.	2.5	18
213	Combination of cytogenetic analysis and molecular screening in patients with de novo acute myeloid leukemia. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 501-510.	1.0	1
214	Establishment of reproducible xenotransplantation model of T cell acute lymphoblastic leukemia in NOD/SCID mice. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 511-516.	1.0	1
215	FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia. <i>International Journal of Hematology</i> , 2012, 96, 234-240.	1.6	7
216	Immune safety of a novel oncolytic mutant M1 after administration In Vivo. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 517-523.	1.0	0

#	ARTICLE	IF	CITATIONS
217	A single fusion signal for t(14;18)(q32;q21) translocation is present in both the follicular lymphoma and local endothelial cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 324-327.	1.0	1
218	Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 358-363.	1.0	8
219	TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 608-613.	1.0	7
220	Interdigitating Dendritic Cell Sarcoma: Case Report with Review of the Literature. Onkologie, 2011, 34, 634-637.	0.8	10
221	Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro. Journal of Huazhong University of Science and Technology [Medical Sciences], 2010, 30, 734-740.	1.0	19
222	Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. Journal of Experimental Medicine, 2010, 207, 505-520.	8.5	137
223	5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. Oncology Reports, 2010, 23, 121-8.	2.6	61
224	Identification of <i>LIV1</i> , a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach. Molecular Cancer Therapeutics, 2009, 8, 3108-3116.	4.1	14
225	Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Letters, 2009, 273, 257-265.	7.2	39
226	Investigation of gene therapy of adenovirus in immune suppression. Frontiers of Medicine in China, 2008, 2, 386-390.	0.1	0
227	Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 213-223.	4.9	24
228	Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene. Cancer Letters, 2008, 271, 205-214.	7.2	21
229	Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecologic Oncology, 2007, 106, 299-304.	1.4	53
230	A Novel Target of Histone Deacetylase Inhibitor, Involves in Mitochondria Membrane Protein Ubiquitination and Regulates Apoptosis.. Blood, 2007, 110, 4187-4187.	1.4	0
231	The Effects of Tcf-1 Gene Silence on Marrow CD4+ T Cells from Aplastic Anemia Patients.. Blood, 2007, 110, 3761-3761.	1.4	0
232	Mobilization, Harvesting and Transplantation of Peripheral Blood Stem Cells in Patients with Severe Refractory Systemic Lupus Erythematosus - A Single Center Experience.. Blood, 2007, 110, 5107-5107.	1.4	0
233	Experiment Therapy of Aplastic Anemia Using Cyclosporin A Combined with IDO Agonist.. Blood, 2007, 110, 1695-1695.	1.4	0
234	Cytotoxic Effects of CML28 Specific T Cells on Acute Leukemia Cells In Vitro.. Blood, 2007, 110, 4886-4886.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1789-1800.	4.9	28
236	Cytarabine and paclitaxel exhibit different cell-cycle specificities in different cell growing status. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 416-419.	0.1	2
237	Reversal of the Malignant Phenotype of Cervical Cancer CaSki Cells through Adeno-Associated Virus-Mediated Delivery of HPV16 E7 Antisense RNA. <i>Clinical Cancer Research</i> , 2006, 12, 2032-2037.	7.0	20
238	Selective Targeting of Checkpoint Kinase 1 in Tumor Cells with a Novel Potent Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2006, 13, 928-937.	8.2	29
239	The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro. <i>Oncology Reports</i> , 2006, 15, 1147-52.	2.6	20
240	Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability. <i>Clinical Cancer Research</i> , 2005, 11, 8431-8440.	7.0	31
241	Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. <i>Oncology Reports</i> , 2005, 14, 275-9.	2.6	17
242	Molecular mechanism of enhanced apoptotic response in U937 cells mediated by sodium butyrate. <i>Chinese Journal of Oncology</i> , 2002, 24, 320-2.	0.1	1
243	Ara-C induced apoptosis in human myeloid leukemia cell line HL-60: Inducing apoptosis is the primary mechanism of chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 1997, 9, 183-187.	2.2	0